Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Astrid A M van der Veldt

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
The New England Journal of Medicine|April 27, 2012
Bevacizumab in neoadjuvant treatment for breast cancerAstrid A M van der Veldt, Egbert F Smit
European Urology|October 16, 2019
Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?Karlijn de Joode, Astrid A M van der Veldt
The New England Journal of Medicine|May 13, 2011
Advances in pancreatic neuroendocrine tumor treatmentAstrid A M van der Veldt, Sebastiaan A Kleijn
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
In vivo imaging as a pharmacodynamic markerAstrid A M van der Veldt, Adriaan A Lammertsma
The Journal of Urology|June 23, 2009
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523Astrid A M van der Veldt, Epie Boven, Axel Bex
The New England Journal of Medicine|November 14, 2019
Drug Effects on the ThyroidLindsay Angus, Robin P Peeters, Astrid A M van der Veldt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Pituitary gland: do anticancer drugs sit in the Turkish saddle?Astrid A M van der Veldt, Egbert F Smit, Adriaan A Lammertsma
Cell Cycle (Georgetown, Tex.)|October 4, 2012
Scheduling of anticancer drugs: timing may be everythingAstrid A M Van der Veldt, Adriaan A Lammertsma, Egbert F Smit
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
[11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kineticsAstrid A M van der Veldt, Adriaan A Lammertsma, N Harry Hendrikse
Thyroid : Official Journal of the American Thyroid Association|April 4, 2013
Reduction in thyroid perfusion after bevacizumab treatmentAstrid A M van der Veldt, Adriaan A Lammertsma, Egbert F Smit
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
The New England Journal of Medicine|April 27, 2012
Bevacizumab in neoadjuvant treatment for breast cancerAstrid A M van der Veldt, Egbert F Smit
European Urology|October 16, 2019
Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?Karlijn de Joode, Astrid A M van der Veldt
The New England Journal of Medicine|May 13, 2011
Advances in pancreatic neuroendocrine tumor treatmentAstrid A M van der Veldt, Sebastiaan A Kleijn
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
In vivo imaging as a pharmacodynamic markerAstrid A M van der Veldt, Adriaan A Lammertsma
The Journal of Urology|June 23, 2009
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523Astrid A M van der Veldt, Epie Boven, Axel Bex
The New England Journal of Medicine|November 14, 2019
Drug Effects on the ThyroidLindsay Angus, Robin P Peeters, Astrid A M van der Veldt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Pituitary gland: do anticancer drugs sit in the Turkish saddle?Astrid A M van der Veldt, Egbert F Smit, Adriaan A Lammertsma
Cell Cycle (Georgetown, Tex.)|October 4, 2012
Scheduling of anticancer drugs: timing may be everythingAstrid A M Van der Veldt, Adriaan A Lammertsma, Egbert F Smit
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
[11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kineticsAstrid A M van der Veldt, Adriaan A Lammertsma, N Harry Hendrikse
Thyroid : Official Journal of the American Thyroid Association|April 4, 2013
Reduction in thyroid perfusion after bevacizumab treatmentAstrid A M van der Veldt, Adriaan A Lammertsma, Egbert F Smit
Pageof 20